Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 3/20 | 0.46 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 8/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1625027 | 1.00 | CHEK2 (0.46) | CHEK2SMAD3BCHEMAPTKMT2A | |
| SCHEMBL1624568 | 0.95 | CHEK2 (0.49) | CHEK2SMAD3BCHEMAPTKMT2A | |
| Hydrochloric Acid SCHEMBL1623170 | 0.95 | CHEK2 (0.48) | CHEK2SMAD3BCHEMAPTKMT2A | |
| SCHEMBL1624542 | 0.92 | CHEK2 (0.47) | CHEK2SMAD3BCHEMAPTKMT2A | |
| SCHEMBL1624504 | 0.90 | CHEK2 (0.49) | CHEK2SMAD3BCHEMAPTKMT2A | |
| SCHEMBL1621584 | 0.90 | CHEK2 (0.49) | CHEK2SMAD3BCHEMAPTKMT2A | |
| SCHEMBL1624731 | 0.89 | CHEK2 (0.48) | CHEK2SMAD3MAPTKMT2AMEN1 | |
| SCHEMBL1622730 | 0.89 | CHEK2 (0.48) | CHEK2SMAD3MAPTKMT2AMEN1 | |
| SCHEMBL1624109 | 0.89 | CHEK2 (0.48) | CHEK2SMAD3MAPTKMT2AMEN1 | |
| SCHEMBL1624102 | 0.88 | CHEK2 (0.48) | CHEK2BCHEMAPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283354-B2 | Voltage gated sodium and calcium channel inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-09 | — | — | US | disclosed |
| US-7928107-B2 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-19 | — | — | US | disclosed |
| US-20090312342-A1 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2009-12-17 | — | — | US | disclosed |
| US-20060173018-A1 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2006-08-03 | — | — | US | disclosed |
| WO-2006028904-A9 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312342-A1 | Quinazolines useful as modulators of ion channels | KCNQ1, KCNQ2, KCNN3 | CHEK2 2935/4885SMAD3 4194/4885BCHE 1444/4885 |
| US-20060173018-A1 | Quinazolines useful as modulators of ion channels | KCNQ1, KCNQ2, KCNN3 | CHEK2 2935/4885SMAD3 4194/4885BCHE 1444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.